Reductions in spontaneous locomotor activity in aged male, but not female, rats in a model of early Parkinson's disease.
The excessive loss of dopamine (DA) neurons that occurs with Parkinson's disease is usually confined to older individuals. While 6-hydroxydopamine (6-OHDA) is often used in animal models of DA neuron degeneration, there have been relatively few studies that have examined the effects of 6-OHDA in older animals. In the present study, we compared the effects of a bilateral, partial lesion with 6-OHDA in young (4 months), middle-aged (14 months), and aged (24 months) Fischer-344 rats of both sexes. Animals were given a single injection of vehicle or 100 mug 6-OHDA into the right lateral ventricle. Four weeks later, spontaneous locomotor activity was monitored. Microdialysis experiments were carried out 1 to 3 days later. The 6-OHDA treatments had no effect on horizontal activity or total distance traveled in young adults. However, with aged rats, there was a decrease in both measures in the vehicle-treated control rats compared to young adult controls, and a further decrease in the lesioned aged male rats. The 6-OHDA treatments led to significant decreases in both potassium- and amphetamine-evoked overflow of DA from the striatum in all groups. Thus, partial bilateral lesions of the nigrostriatal DA system led to decreases in evoked release of DA in the striatum of male and female rats of all three ages, but to changes in spontaneous activity only in the aged males. These results indicate that there are both age and sex differences in the brain's response to 6-OHDA, and imply that compensatory or neuroprotective mechanisms in the young brain and aged female brain are more efficient than in the aged male brain.
Cass
Wayne A
WA
Department of Anatomy and Neurobiology, MN-225 Chandler Medical Center, University of Kentucky, Lexington, KY 40536-0298, USA. wacass1@uky.edu
Peters
Laura E
LE
Smith
Michael P
MP
D000222:Adaptation, Physiological / Q000502:physiology; D018663:Adrenergic Agents / Q000494:pharmacology; D000367:Age Factors; D000375:Aging / Q000502:physiology*; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D045604:Extracellular Fluid / Q000187:drug effects / Q000378:metabolism; D005260:Female; D007276:Injections, Intraventricular; D008297:Male; D017551:Microdialysis; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology*; D016627:Oxidopamine / Q000494:pharmacology; D020734:Parkinsonian Disorders / Q000139:chemically induced / Q000503:physiopathology*; D011188:Potassium / Q000378:metabolism; D051381:Rats; D011916:Rats, Inbred F344; D012737:Sex Factors; D013378:Substantia Nigra / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology
D018663:Adrenergic Agents; D016627:Oxidopamine; D011188:Potassium; D004298:Dopamine